Abstract 3582
Background
Resistance to immune checkpoint inhibitors (ICIs) is a major unmet medical need. The TGF-beta pathway is a key immunosuppressive mechanism that correlates with resistance to PD-1/PD-L1 inhibitors. TGF-beta acts by inhibiting the recruitment and activation of anti-tumor T-cells, either directly, or indirectly through its action on cancer-associated fibroblasts. AVID200 is a receptor ectodomain trap that was rationally-designed to inhibit with pM potency TGF-beta1 and -beta3, the principal oncogenic TGF-beta isoforms. Targeting these two isoforms with AVID200 has the potential to increase the number of patients that benefit from ICIs.
Methods
The percent of patients exhibiting tumor over-expression (>30FPKM) of TGF-beta isoforms was analyzed in > 10,000 samples from the CGA RNAseq data. The potency and selectivity of AVID200 and other clinical stage TGF-beta inhibitors was assessed using an A549 cell-based. The ability of AVID200 to enhance the tumor-cell killing activity of T-cells was evaluated in vivo in a syngeneic 4T1 cancer model. The ability of AVID200 to enhance T-cell infiltration and the efficacy of ICIs was assessed in EMT-6 and MC-38 cancer models.
Results
Gene expression analysis revealed that TGF-beta1 is the predominant isoform expressed in solid tumors, with TGF-beta3 also being expressed in multiple tumor types. This indicates that it is important to target both ligand isoforms for maximal efficacy, particularly because TGF-beta 1 and 3 can functionally substitute for each other. In vitro, AVID200 exhibited the best potency (low pM) and selectivity for TGF-beta 1 & 3 vs TGF-beta 2 amongst the TGF-beta inhibitors tested. Having minimal activity on TGF-beta2 is desirable because TGF-beta2 is involved in cardiac homeostasis and the positive regulation of hematopoiesis. In vivo, AVID200 was shown to promote T-cell infiltration and to increase the anti-tumor activity of ICIs.
Conclusions
In conclusion, AVID200 efficiently neutralizes TGF-beta 1 and 3, the main oncogenic isoforms, with best-in-class potency and sensitizes tumors to immune checkpoint blockade. The AVID200 Phase 1 study in patients with solid tumors is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Forbius (Formation Biologics).
Funding
Forbius (Formation Biologics).
Disclosure
T. Gruosso: Full / Part-time employment: Forbius (Formation Biologics). M. O’Connor: Leadership role, Licensing / Royalties, Full / Part-time employment, Officer / Board of Directors: Forbius (Formation Biologics). J. Denis: Full / Part-time employment: Forbius (Formation Biologics). R. Figueredo: Research grant / Funding (self): Forbius (Formation Biologics); Research grant / Funding (self): Trillium Therapeutics, Inc.; Research grant / Funding (self): Critical Outcome Technologies, Inc. J. Koropatnick: Licensing / Royalties: Sarissa Inc; Research grant / Funding (self): Forbius (Formation Biologics); Research grant / Funding (self): Trillium Therapeutics, Inc; Research grant / Funding (self): Critical Outcome Technologies, Inc. G. Tremblay: Licensing / Royalties: Alethia Biotherapeutics; Full / Part-time employment: Forbius (Formation Biologics). I.A. Tikhomirov: Leadership role, Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment, Officer / Board of Directors: Forbius (Formation Biologics).
Resources from the same session
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract